Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
Ten Long-Term Impacts of COVID-19 on Biopharma
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski
Blog
Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake.
Payers are still at very different stages in their acceptance of DTx, and...
Blog
2019 NRDL: Insights for Future Pricing Negotiations in China
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed...
